Drug therapy: Drug metabolism and variability among patients in drug response

New England Journal of Medicine

Volumn 352, Issue 21, 2005, Pages

  Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; ALPRENOLOL; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; AMOXICILLIN; ATORVASTATIN; BROMOCRIPTINE; BUFURALOL; CAPTOPRIL; CARBAMAZEPINE; CARVEDILOL; CIMETIDINE; CLARITHROMYCIN; CLOMIPRAMINE; CODEINE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DELAVIRDINE; DESIPRAMINE; DEXTROMETHORPHAN; DICLOFENAC; DILTIAZEM; DRUG METABOLIZING ENZYME; EFAVIRENZ; ERYTHROMYCIN; FELODIPINE; FLECAINIDE; FLUOXETINE; GLIPIZIDE; GLUCURONOSYLTRANSFERASE; HALOPERIDOL; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LABETALOL; LANSOPRAZOLE; LOSARTAN; MACROLIDE; MERCAPTOPURINE; METHYLTRANSFERASE; METOPROLOL; METRONIDAZOLE; MEVINOLIN; MEXILETINE; MICONAZOLE; MIDAZOLAM; MIFEPRISTONE; MORPHINE; NALOXONE; NEFAZODONE; NEVIRAPINE; NICARDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; NITROIMIDAZOLE; NORTRIPTYLINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PAROXETINE; PERPHENAZINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PROPAFENONE; PROPRANOLOL; PROTEINASE INHIBITOR; QUINIDINE; RABEPRAZOLE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SPIRONOLACTONE; SULFINPYRAZONE; TACRINE; TACROLIMUS; TERBUTALINE; THIOL ESTER HYDROLASE; TIMOLOL; TOLBUTAMIDE; TRIAZOLAM; TROLEANDOMYCIN; VENLAFAXINE; VERAPAMIL; WARFARIN; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A PROTEIN, MOUSE; CYTOCHROME P450; DRUG; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

BLEEDING; BREAKTHROUGH BLEEDING; CARDIOTOXICITY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; DRUG SULFATION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HEADACHE; HUMAN; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; VAGINA BLEEDING; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG INTERACTION; GENETICS; METABOLISM; PHARMACOGENETICS;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 19444376971     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra032424     Document Type: Review

References (50)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2002;7:201-4.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62.
4. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904.
5. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:10l-10.
6. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
7. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997;27:99-127.
8. Capewell S, Freestone S, Critchley JAJH, Pottage A, Prescott LF. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;2:480-2.
9. Thummel KE, Wilkinson GR. In vitro and in vivo interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
10. Levy RH, Thummel KE, Trager WE, et al. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000.
11. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
12. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000;75:933-42.
13. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000;40:649-74.
14. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-56.
15. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355:548-9.
16. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8.
17. [Erratum, Lancet 2001;357:1210.]
18. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-66.
19. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
20. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol 2002;36:832-50.
21. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
22. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
23. Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.
24. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003;348:1170-5.
25. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999;9:435-43.
26. Bertilsson L, Dahl M-L, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
27. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-37.
28. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-46.
29. Dalén P, Frengell C, Dahl M-L, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997;19:543-4.
30. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31.
31. [Erratum, N Engl J Med 2005;352:638.]
32. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002;315:137-55.
33. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-47.
34. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000;61:174-83.
35. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552-61.
36. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-30.
37. Furuta T, Takashima M, Shirai N, et al. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 2000;67:684-9.
38. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-68.
39. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001;70:391-4.
40. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.
41. [Erratum, Pharmacogenetics 2002;12:343.]
42. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52.
43. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
44. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl:204S-233S.
45. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-28.
46. Lenfant C. Shattuck Lecture: clinical research to clinical practice - lost in translation? N Engl J Med 2003;349:868-74.
47. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
48. Chou WH, Yan F-X, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000;20:246-51.
49. Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care 2003;9:493-500.
50. Food and Drug Administration. Medical devices: clinical chemistry and clinical toxicology devices; drug metabolizing enzyme genotyping system. Fed Regist 2005;70(46):11865-7.